Astellas, MD Anderson: Agreement to Research, Develop AML Treatment

Astellas, MD Anderson: Agreement to Research, Develop AML Treatment

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

Source: www.dddmag.com



Comments are closed.